Investors

/Investors
Investors 2020-01-09T21:53:14+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

5.21
-0.04 (-0.71%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :29,229
Date :01-29-2020

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

January 28th, 2020|Comments Off on Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

Protease inhibitor is a key component of platform technology that protects therapeutic proteins in the digestive system NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage [...]

Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

January 23rd, 2020|Comments Off on Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to [...]

Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

January 21st, 2020|Comments Off on Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, [...]

Oramed Pharmaceuticals Issues Letter to Shareholders

January 9th, 2020|Comments Off on Oramed Pharmaceuticals Issues Letter to Shareholders

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter [...]